These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 3140797

  • 21. Dose response studies using desferrioxamine and orally active chelators in a mouse model.
    Kontoghiorghes GJ.
    Scand J Haematol; 1986 Jul; 37(1):63-70. PubMed ID: 3764334
    [Abstract] [Full Text] [Related]

  • 22. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
    Florence A, Ward RJ, Peters TJ, Crichton RR.
    Biochem Pharmacol; 1992 Sep 25; 44(6):1023-7. PubMed ID: 1417929
    [Abstract] [Full Text] [Related]

  • 23. Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload.
    Kontoghiorghes GJ, Barr J, Nortey P, Sheppard L.
    Am J Hematol; 1993 Apr 25; 42(4):340-9. PubMed ID: 8493983
    [Abstract] [Full Text] [Related]

  • 24. Effect of hydrogen peroxide on prostaglandin production and cellular integrity in cultured porcine aortic endothelial cells.
    Whorton AR, Montgomery ME, Kent RS.
    J Clin Invest; 1985 Jul 25; 76(1):295-302. PubMed ID: 2991339
    [Abstract] [Full Text] [Related]

  • 25. Removal of thallium by combining desferrioxamine and deferiprone chelators in rats.
    Amiri A, Fatemi SJ, Fatemi SN.
    Biometals; 2007 Apr 25; 20(2):159-63. PubMed ID: 16927173
    [Abstract] [Full Text] [Related]

  • 26. Curcumin contributes to in vitro removal of non-transferrin bound iron by deferiprone and desferrioxamine in thalassemic plasma.
    Srichairatanakool S, Thephinlap C, Phisalaphong C, Porter JB, Fucharoen S.
    Med Chem; 2007 Sep 25; 3(5):469-74. PubMed ID: 17897073
    [Abstract] [Full Text] [Related]

  • 27. Fluoride stimulates in vitro vascular prostacyclin synthesis: interrelationship of G proteins and protein kinase C.
    Jeremy JY, Dandona P.
    Eur J Pharmacol; 1988 Feb 09; 146(2-3):279-84. PubMed ID: 3131147
    [Abstract] [Full Text] [Related]

  • 28. In vivo evaluation of hydroxypyridone iron chelators in a mouse model.
    Gyparaki M, Porter JB, Hirani S, Streater M, Hider RC, Huehns ER.
    Acta Haematol; 1987 Feb 09; 78(2-3):217-21. PubMed ID: 3120475
    [Abstract] [Full Text] [Related]

  • 29. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
    Boelaert JR, Van Cutsem J, de Locht M, Schneider YJ, Crichton RR.
    Kidney Int; 1994 Mar 09; 45(3):667-71. PubMed ID: 8196268
    [Abstract] [Full Text] [Related]

  • 30. Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytes.
    Maclean KH, Cleveland JL, Porter JB.
    Blood; 2001 Dec 15; 98(13):3831-9. PubMed ID: 11739193
    [Abstract] [Full Text] [Related]

  • 31. New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones.
    Kontoghiorghes GJ, Sheppard L, Chambers S.
    Arzneimittelforschung; 1987 Oct 15; 37(10):1099-102. PubMed ID: 3435580
    [Abstract] [Full Text] [Related]

  • 32. Binding of aluminium to plasma proteins: comparative effect of desferrioxamine and deferiprone (L1).
    Fernández-Martín JL, Menéndez-Fraga P, Canteros MA, Díaz-López JB, Cannata-Andía JB.
    Clin Chim Acta; 1994 Oct 31; 230(2):137-45. PubMed ID: 7834865
    [Abstract] [Full Text] [Related]

  • 33. In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis.
    Hoyes KP, Jones HM, Abeysinghe RD, Hider RC, Porter JB.
    Exp Hematol; 1993 Jan 31; 21(1):86-92. PubMed ID: 8417963
    [Abstract] [Full Text] [Related]

  • 34. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells.
    Cragg L, Hebbel RP, Miller W, Solovey A, Selby S, Enright H.
    Blood; 1998 Jul 15; 92(2):632-8. PubMed ID: 9657765
    [Abstract] [Full Text] [Related]

  • 35. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
    Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C.
    J Lab Clin Med; 2001 Aug 15; 138(2):130-8. PubMed ID: 11477380
    [Abstract] [Full Text] [Related]

  • 36. RU486 antagonizes the inhibitory action of progesterone on prostacyclin and thromboxane A2 synthesis in cultured rat myometrial explants.
    Jeremy JY, Dandona P.
    Endocrinology; 1986 Aug 15; 119(2):655-60. PubMed ID: 3089760
    [Abstract] [Full Text] [Related]

  • 37. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
    Chaston TB, Lovejoy DB, Watts RN, Richardson DR.
    Clin Cancer Res; 2003 Jan 15; 9(1):402-14. PubMed ID: 12538494
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
    Bergeron RJ, Streiff RR, Wiegand J, Luchetta G, Creary EA, Peter HH.
    Blood; 1992 Apr 01; 79(7):1882-90. PubMed ID: 1558978
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.